News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
718,498 Results
Type
Article (42558)
Company Profile (295)
Press Release (675645)
Multimedia
Podcasts (79)
Webinars (12)
Section
Business (210498)
Career Advice (2091)
Deals (36637)
Drug Delivery (107)
Drug Development (83113)
Employer Resources (175)
FDA (16580)
Job Trends (15410)
News (356171)
Policy (33929)
Tag
2024 BioCapital Digital (12)
2024 BioForest Digital (4)
2024 BioForest Standard (1)
2024 BioMidwest Digital (9)
2024 BioMidwest Standard (1)
2024 Bio NC Digital (7)
2024 Bio NC Standard (1)
2024 Biotech Bay Standard (18)
2024 Biotech Beach Digital (9)
2024 Biotech Beach Standard (5)
2024 Genetown Digital (8)
2024 Genetown Standard (10)
2024 Lone Star Bio Digital (5)
2024 Pharm Country Digital (6)
2024 Pharm Country Standard (5)
2025 BioForest Digital (3)
2025 Lone Star Bio Digital (6)
2026 BioCapital Standard (1)
2026 BioMidwest Elite (1)
2026 Bio NC Standard (1)
2026 Biotech Bay Standard (1)
2026 Biotech Beach Elite (1)
2026 Genetown Elite (2)
2026 Genetown Standard (1)
2026 Pharm Country Standard (2)
Academia (2601)
Accelerated approval (5)
Adcomms (21)
Allergies (89)
Alliances (51472)
ALS (92)
Alzheimer's disease (1396)
Antibody-drug conjugate (ADC) (133)
Approvals (16585)
Artificial intelligence (267)
Autoimmune disease (23)
Automation (16)
Bankruptcy (371)
Best Places to Work (11772)
BIOSECURE Act (20)
Biosimilars (111)
Biotechnology (189)
Bladder cancer (78)
Brain cancer (29)
Breast cancer (281)
Cancer (2289)
Cardiovascular disease (182)
Career advice (1751)
Career pathing (31)
CAR-T (151)
Cell therapy (426)
Cervical cancer (20)
Clinical research (67556)
Collaboration (856)
Compensation (529)
Complete response letters (25)
COVID-19 (2660)
CRISPR (45)
C-suite (245)
Cystic fibrosis (103)
Data (2201)
Decentralized trials (2)
Denatured (28)
Depression (44)
Diabetes (272)
Diagnostics (6451)
Digital health (19)
Diversity (8)
Diversity, equity & inclusion (44)
Drug discovery (124)
Drug pricing (111)
Drug shortages (28)
Duchenne muscular dystrophy (94)
Earnings (88242)
Editorial (38)
Employer branding (21)
Employer resources (149)
Events (115222)
Executive appointments (733)
FDA (17839)
Featured Employer (50)
Fibrodysplasia Ossificans Progressiva (1)
Friedreich's ataxia (4)
Frontotemporal dementia (7)
Funding (757)
Gene editing (110)
Generative AI (21)
Gene therapy (316)
GLP-1 (745)
Government (4538)
Grass and pollen (5)
Guidances (54)
Healthcare (19001)
Huntington's disease (24)
IgA nephropathy (28)
Immunology and inflammation (124)
Indications (30)
Infectious disease (2803)
Inflammatory bowel disease (140)
Inflation Reduction Act (8)
Influenza (51)
Intellectual property (98)
Interviews (322)
IPO (16787)
IRA (47)
Job creations (4057)
Job search strategy (1492)
Kidney cancer (10)
Labor market (38)
Layoffs (488)
Leadership (17)
Legal (8380)
Liver cancer (76)
Lung cancer (322)
Lymphoma (154)
Machine learning (7)
Management (59)
Manufacturing (316)
MASH (68)
Medical device (13459)
Medtech (13464)
Mergers & acquisitions (20388)
Metabolic disorders (702)
Multiple sclerosis (79)
NASH (17)
Neurodegenerative disease (93)
Neuropsychiatric disorders (29)
Neuroscience (1947)
NextGen: Class of 2025 (6639)
Non-profit (4529)
Northern California (2659)
Now hiring (39)
Obesity (376)
Opinion (230)
Ovarian cancer (77)
Pain (93)
Pancreatic cancer (84)
Parkinson's disease (150)
Partnered (21)
Patents (237)
Patient recruitment (110)
Peanut (49)
People (59270)
Pharmaceutical (91)
Pharmacy benefit managers (19)
Phase I (20951)
Phase II (29722)
Phase III (22278)
Pipeline (1187)
Policy (150)
Postmarket research (2655)
Preclinical (8931)
Press Release (68)
Prostate cancer (108)
Psychedelics (31)
Radiopharmaceuticals (253)
Rare diseases (396)
Real estate (6259)
Recruiting (67)
Regulatory (23136)
Reports (46)
Research institute (2369)
Resumes & cover letters (358)
Rett syndrome (5)
RNA editing (5)
RSV (42)
Schizophrenia (75)
Series A (132)
Series B (85)
Service/supplier (12)
Sickle cell disease (55)
Southern California (2293)
Special edition (15)
Spinal muscular atrophy (150)
Sponsored (30)
Startups (3728)
State (2)
Stomach cancer (14)
Supply chain (69)
Tariffs (41)
The Weekly (49)
United States (23138)
Vaccines (703)
Venture capitalists (41)
Weight loss (250)
Women's health (35)
Worklife (15)
Date
Today (208)
Last 7 days (918)
Last 30 days (2734)
Last 365 days (33368)
2025 (10605)
2024 (35787)
2023 (40646)
2022 (51809)
2021 (56338)
2020 (54801)
2019 (47413)
2018 (35787)
2017 (33154)
2016 (32673)
2015 (38623)
2014 (32525)
2013 (27640)
2012 (29734)
2011 (30501)
2010 (28507)
Location
Africa (782)
Alabama (53)
Alaska (7)
Arizona (238)
Arkansas (14)
Asia (40748)
Australia (6524)
California (6095)
Canada (2014)
China (534)
Colorado (268)
Connecticut (273)
Delaware (149)
Europe (87009)
Florida (904)
Georgia (203)
Idaho (57)
Illinois (542)
India (26)
Indiana (315)
Iowa (11)
Japan (161)
Kansas (104)
Kentucky (23)
Louisiana (10)
Maine (62)
Maryland (894)
Massachusetts (4595)
Michigan (218)
Minnesota (390)
Mississippi (2)
Missouri (81)
Montana (27)
Nebraska (25)
Nevada (63)
New Hampshire (63)
New Jersey (1726)
New Mexico (29)
New York (1737)
North Carolina (980)
North Dakota (8)
Northern California (2659)
Ohio (202)
Oklahoma (14)
Oregon (39)
Pennsylvania (1377)
Puerto Rico (12)
Rhode Island (33)
South America (1163)
South Carolina (22)
South Dakota (1)
Southern California (2293)
Tennessee (101)
Texas (906)
Utah (182)
Virginia (152)
Washington D.C. (61)
Washington State (558)
West Virginia (3)
Wisconsin (56)
718,498 Results for "ligand pharmaceuticals inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Ligand Subsidiary Pelthos Therapeutics to Combine with Channel Therapeutics
April 17, 2025
·
13 min read
Press Releases
Ligand to Report First Quarter 2025 Financial Results on May 8, 2025
April 24, 2025
·
2 min read
Press Releases
Ligand to Participate in March 2025 Investor Conferences
March 4, 2025
·
2 min read
Press Releases
Ligand Leads $75 Million Royalty Financing in Castle Creek Biosciences
February 26, 2025
·
6 min read
BioMidwest
Ligand to Participate in Upcoming May 2024 Investor Conferences
Ligand Pharmaceuticals Incorporated announced that Todd Davis and Tavo Espinoza will participate in the following upcoming investor conferences: Craig-Hallum Institutional Investor Conference.
May 23, 2024
·
2 min read
Press Releases
Ligand Reports Fourth Quarter and Full Year 2024 Financial Results
February 27, 2025
·
33 min read
Press Releases
Shuttle Pharma Developing Pretreatment Diagnostic Blood Tests for Prostate Cancer, Files Provisional Patent for PSMA Ligand Conjugates to Treat Prostate Cancer
April 11, 2025
·
6 min read
Deals
Ligand Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that effective March 1, 2024, Ligand’s Human Capital Management and Compensation Committee approved the grant of a non-qualified stock option award to purchase 15,100 shares of its common stock to one non-executive employee.
March 4, 2024
·
2 min read
BioMidwest
Ligand and Agenus Enter Into $100 Million Royalty Financing Agreement
Ligand Pharmaceuticals Incorporated and Agenus Inc. announced that the companies have entered into a royalty financing agreement to support Agenus’ key development initiatives in the ongoing BOT/BAL clinical development program.
May 7, 2024
·
11 min read
Business
Ligand Reports First Quarter 2024 Financial Results
Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today reported financial results for the three months ended March 31, 2024, and provided an operating forecast and business updates.
May 7, 2024
·
22 min read
1 of 71,850
Next
